VIPRF dividend yield: 4.00%. MRK dividend yield: 3.25%. VIPRF is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in VIPRF shares. Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.
VIPRF is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in VIPRF shares.
Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.
Is VIPRF or MRK better for dividend income in 2026?
VIPRF currently offers a 4.00% yield (2.00/share/year) while MRK offers 3.25% (3.08/share/year). VIPRF provides higher current income. However, MRK has grown its dividend faster (8.2% 5Y CAGR), which may lead to better long-term income through compounding.
How much would $10,000 in VIPRF vs MRK earn per year?
With $10,000 invested today: VIPRF pays approximately $400/year. MRK pays approximately $325/year. With DRIP reinvestment over 10 years, these grow to $899/year (VIPRF) and $950/year (MRK).
Does VIPRF or MRK pay monthly dividends?
VIPRF pays quarterly dividends. MRK pays quarterly dividends. Neither pay monthly — both use a quarterly schedule, which is preferred by investors who need regular cash flow.
📬
Get this VIPRF vs MRK comparison by email
Save your analysis + get weekly dividend insights. Free forever.